

Van: [ccmo_bi](#)
Aan: [ccmo_frontoffice](#); [ccmo_eudract](#)
Onderwerp: FW: NL69548.056.19: Notification premature termination
Datum: woensdag 29 januari 2020 10:03:02
Bijlagen: [image001.png](#)
[A1 - Cover letter applicant CCMO dated 29 January 2020.pdf](#)
[B7 - EudraCT form End of Trial CCMO dated 29 January 2020.pdf](#)

Einde studie voor Marjolein.

Groet, 5.1.2.e

Van: 5.1.2.e <5.1.2.e@qps.com>
Verzonden: woensdag 29 januari 2020 09:48
Aan: ccmo_bi <bi@ccmo.nl>
CC: 5.1.2.e <5.1.2.e@qps.com>; 5.1.2.e <5.1.2.e@qps.com>
Onderwerp: NL69548.056.19: Notification premature termination

Dear members of the CCMO,

Herewith QPS Netherlands B.V. sends the premature termination documentation of the study “A two-part parallel group study to assess the safety, tolerability and pharmacokinetic (PK) profile of multiple oral doses of RDN-929 in healthy older adults and subjects with early symptomatic Alzheimer’s Disease” to the CCMO for notification.

On 07 January 2020, we submitted a substantial amendment requesting a temporarily halt to the study.

During this hold period, we evaluated all of the data from the latest case (subject 5.1.2.e); the extended hepatic lab panel and hepatic/biliary ultrasound assessments did not demonstrate other reasons for the liver transaminase elevations. Given the available data, including the occurrence of the three cases with similar patterns of liver transaminase elevations and probable relation to study drug, the decision was made to permanently terminate the study effective 22 January 2020. Ultimately, the data demonstrate that the risks of the trial outweigh the benefits and the safety of the clinical trial subjects may be adversely affected.

The date of last subject last visit was 21 January 2020.

The following documents are enclosed:

- A1 – Cover letter applicant CCMO, dated 29 January 2020
- B7 – EudraCT form End of Trial CCMO, dated 29 January 2020

With Kind regards/Met vriendelijke groeten,



5.1.2.e
5.1.2.e
QPS Netherlands BV | Petrus Campersingel 123 | 9713 AG
Groningen | The Netherlands
Tel +31 50 368 5.1.2.e
Email 5.1.2.e@qps.com | Web www.qps.com

Please note that I am not in the office on Friday

This email or fax and any attachments may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments. Thank you.

QPS is a GLP/GCP-compliant CRO that supports discovery, preclinical, and clinical drug development. We provide quality services in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Early & Late Phase Clinical Research to clients worldwide. Our 30+ regional laboratories, clinical facilities and offices are located in North America, Europe, India and Asia. For more information, visit <http://www.qps.com>.